Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare

PartnershipPositive

AI Analysis

Summary

Eli Lilly announced a $3.35 billion drug discovery partnership with China-based InnoCare, a biopharma company with three approved therapies focused on cancer and autoimmune disease treatments.

Importance:7/10

Sentiment:

0.50

acquisitionpartnershipdrug discoverycancerautoimmune diseaseChina

Related Companies

$LLY

Read the original article

Published by Pharmaceutical Technology on September 24, 2026 1:57 PM

Read Original